MaxCyte, Inc. Enters into Strategic Platform License with TG Therapeutics
Rockville, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.
MaxCyte, Inc.: Pioneering Cell Engineering
MaxCyte, Inc. is revolutionizing the field of cell engineering with their innovative platform technologies. By providing enabling tools for the discovery, development, and commercialization of cell-based therapeutics, MaxCyte is at the forefront of advancing medical science. Their commitment to pushing the boundaries of what is possible in cellular therapies is evident in their latest partnership with TG Therapeutics.
TG Therapeutics: A Focus on B-Cell Diseases
TG Therapeutics is a biopharmaceutical company dedicated to finding novel treatments for B-cell diseases. With a fully integrated approach to drug development and commercialization, TG Therapeutics is a key player in the biopharmaceutical industry. By teaming up with MaxCyte, they are poised to take their research and development efforts to the next level.
Together, MaxCyte and TG Therapeutics are set to make significant strides in the field of cell-based therapeutics, ultimately leading to better outcomes for patients suffering from B-cell diseases. This strategic platform license represents a collaboration that has the potential to transform the way these diseases are treated and managed.
How This Partnership Will Affect Me
As a patient with a B-cell disease, this partnership between MaxCyte and TG Therapeutics could have a direct impact on my treatment options. By leveraging cutting-edge cell engineering technologies, this collaboration may lead to the development of more effective and targeted therapies for B-cell diseases. Overall, this partnership has the potential to improve the quality of care available to patients like me.
How This Partnership Will Affect the World
On a larger scale, this partnership between MaxCyte and TG Therapeutics has the potential to reshape the landscape of biopharmaceutical innovation. By combining their expertise and resources, these two companies are positioned to make significant advancements in the development of cell-based therapeutics. This collaboration has the potential to benefit patients around the world by bringing new and improved treatment options to market.
Conclusion
The strategic platform license between MaxCyte, Inc. and TG Therapeutics marks a significant milestone in the field of cell-based therapeutics. By joining forces, these two companies have the opportunity to drive innovation and progress in the treatment of B-cell diseases. This partnership has the potential to not only benefit patients in need of new treatment options but also to make a lasting impact on the future of biopharmaceutical research and development.
